These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 16819501)

  • 1. The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites.
    Garcia-Tsao G
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jul; 3(7):380-9. PubMed ID: 16819501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.
    Salerno F; Cammà C; Enea M; Rössle M; Wong F
    Gastroenterology; 2007 Sep; 133(3):825-34. PubMed ID: 17678653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
    Bureau C; Thabut D; Oberti F; Dharancy S; Carbonell N; Bouvier A; Mathurin P; Otal P; Cabarrou P; Péron JM; Vinel JP
    Gastroenterology; 2017 Jan; 152(1):157-163. PubMed ID: 27663604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transjugular intrahepatic portosystemic shunt in the management of refractory ascites.
    Garcia-Tsao G
    Semin Intervent Radiol; 2005 Dec; 22(4):278-86. PubMed ID: 21326706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.
    Bucsics T; Hoffman S; Grünberger J; Schoder M; Matzek W; Stadlmann A; Mandorfer M; Schwabl P; Ferlitsch A; Peck-Radosavljevic M; Trauner M; Karner J; Karnel F; Reiberger T
    Liver Int; 2018 Jun; 38(6):1036-1044. PubMed ID: 29091351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded polytetrafluoroethylene (ePTFE)-covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis.
    Zhu P; Dong S; Sun P; Belgaumkar AP; Sun Y; Cheng X; Zheng Q; Li T
    Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012358. PubMed ID: 37531575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.
    Tan HK; James PD; Sniderman KW; Wong F
    J Gastroenterol Hepatol; 2015 Feb; 30(2):389-95. PubMed ID: 25168607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial.
    Riggio O; Ridola L; Angeloni S; Cerini F; Pasquale C; Attili AF; Fanelli F; Merli M; Salvatori FM
    J Hepatol; 2010 Aug; 53(2):267-72. PubMed ID: 20537753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites: a retrospective cohort study.
    Maleux G; Perez-Gutierrez NA; Evrard S; Mroue A; Le Moine O; Laleman W; Nevens F
    Acta Gastroenterol Belg; 2010; 73(3):336-41. PubMed ID: 21086935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of the refractory ascites: Total paracentesis vs. TIPS.
    La Mura V; Salerno F
    Gastroenterol Hepatol; 2016; 39(7):477-80. PubMed ID: 26596208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival benefit of TIPS versus serial paracentesis in patients with refractory ascites: a single institution case-control propensity score analysis.
    Gaba RC; Parvinian A; Casadaban LC; Couture PM; Zivin SP; Lakhoo J; Minocha J; Ray CE; Knuttinen MG; Bui JT
    Clin Radiol; 2015 May; 70(5):e51-7. PubMed ID: 25758602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Transjugular Intrahepatic Portosystemic Shunt versus Large-Volume Paracentesis in Refractory Ascites: Results of a Markov Model Incorporating Individual Patient-Level Meta-Analysis and Nationally Representative Cost Data.
    Kwan SW; Allison SK; Gold LS; Shin DS
    J Vasc Interv Radiol; 2018 Dec; 29(12):1705-1712. PubMed ID: 30392803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial.
    Perarnau JM; Le Gouge A; Nicolas C; d'Alteroche L; Borentain P; Saliba F; Minello A; Anty R; Chagneau-Derrode C; Bernard PH; Abergel A; Ollivier-Hourmand I; Gournay J; Ayoub J; Gaborit C; Rusch E; Giraudeau B;
    J Hepatol; 2014 May; 60(5):962-8. PubMed ID: 24480619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution.
    Martinet JP; Fenyves D; Legault L; Roy L; Dufresne MP; Spahr L; Lafortune M; Pomier-Layrargues G
    Dig Dis Sci; 1997 Jan; 42(1):161-6. PubMed ID: 9009133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
    Colombato L
    J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience.
    Lodato F; Berzigotti A; Lisotti A; Azzaroli F; Mosconi C; Giampalma E; Renzulli M; Cappelli A; Buonfiglioli F; Calvanese C; Zoli M; Golfieri R; Mazzella G
    Scand J Gastroenterol; 2012 Dec; 47(12):1494-500. PubMed ID: 22958120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.
    Narahara Y; Kanazawa H; Fukuda T; Matsushita Y; Harimoto H; Kidokoro H; Katakura T; Atsukawa M; Taki Y; Kimura Y; Nakatsuka K; Sakamoto C
    J Gastroenterol; 2011 Jan; 46(1):78-85. PubMed ID: 20632194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
    Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
    Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
    United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.